ImmunoGen
Presence
AbbVie is one of the...
AbbVie is a company listed under the stock ticker ABBV (US).
AbbVie has a direct presence in 24 countries.AbbVie has 32 subsidiaries including AbbVie APAC, AbbVie Australia and AbbVie Belgium.
They are in:
- Pharmaceuticals85%
- Biotechnology9%
- Other6%
Acquisition, funding and merger involving AbbVie.
- AbbVie has announced the acquisition of ImmunoGen (posted on November 30 2023).
Executives
View the org chart displaying its 14 main executives
Most searched biographies at ImmunoGen
- Mark Enyedy, Director, Chief Executive Officer and President
- Lauren White, Senior Vice President and Chief Financial Officer
- Isabel Kalofonos, Senior Vice President and Chief Commercial Offic...
Popular executive movements at ImmunoGen
- Lauren White has joined the company as Senior Vice President and Chief Financial Officer (posted on September 19 2023).
- Michael Vasconcelles, who was Executive Vice President, Research, Development and Medical Affairs, is promoted to Chief Medical Officer (posted on July 31 2023).
- Anna Berkenblit, Senior Vice President and Chief Medical Officer, has left the company (posted on July 31 2023).
Popular executive movements at AbbVie
- Robert Michael who is President and Chief Operating Officer, will be promoted to Chief Executive Officer and Director on Jul. 1, 2024 (posted on February 21 2024).
- Richard Gonzalez who is Chairman and Chief Executive Officer, will become Executive Chairman of the Board on Jul. 1, 2024 (posted on February 21 2024).
- Susan Quaggin has joined the company as Director (posted on October 13 2023).
Click here to view some more movements at AbbVie
Create your alert
to follow the executive moves at ImmunoGen.
Biotechnology
AbbVie has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by ImmunoGen
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ImmunoGen, Inc.
- ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results | ImmunoGen, Inc.
- ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results | ImmunoGen, Inc.
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ImmunoGen, Inc.
- ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates | ImmunoGen, Inc.
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ImmunoGen, Inc.
- ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO | ImmunoGen, Inc.
- ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences | ImmunoGen, Inc.
- ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review | ImmunoGen, Inc.
- ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference | ImmunoGen, Inc.
- View more press releases Close
Social media about ImmunoGen
- ImmunoGen on Wikipedia, Google News & Yahoo Finance
- ImmunoGen on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Mark Enyedy 
